Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

Research output: Contribution to journalReview article

Abstract

Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

Original languageEnglish
JournalRespiratory Investigation
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Clinical Trials
Therapeutics
Thorax
Neoplasms

Keywords

  • Chemoradiotherapy
  • Durvalumab
  • Immune checkpoint inhibitor
  • Lung cancer
  • Stage III

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{84809d9adba947d5b4a898054404a913,
title = "Recent trends in the treatment of unresectable stage III non-small-cell lung cancer",
abstract = "Approximately 20–25{\%} of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.",
keywords = "Chemoradiotherapy, Durvalumab, Immune checkpoint inhibitor, Lung cancer, Stage III",
author = "Go Makimoto and Katsuyuki Hotta and Katsuyuki Kiura",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.resinv.2019.03.004",
language = "English",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

AU - Makimoto, Go

AU - Hotta, Katsuyuki

AU - Kiura, Katsuyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

AB - Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

KW - Chemoradiotherapy

KW - Durvalumab

KW - Immune checkpoint inhibitor

KW - Lung cancer

KW - Stage III

UR - http://www.scopus.com/inward/record.url?scp=85064154380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064154380&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2019.03.004

DO - 10.1016/j.resinv.2019.03.004

M3 - Review article

C2 - 31000495

AN - SCOPUS:85064154380

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

ER -